Antimicrobial photodynamic therapy is emerging as a promising therapeutic modality for bacterial infections. For optimizing the antibacterial activity of the photosensitizer m-tetrahydroxy-phenylchlorin, it has been encapsulated in mixed cationic liposomes composed of different ratios of dimyristoyl-sn-glycero-phosphatidylcholine and any of four cationic surfactants derived from L-prolinol. The delivery efficiency of the different liposomes formulations has been evaluated on a methicillin-resistant Staphylococcus aureus bacterial strain (MRSA), and one of the tested formulations shows a biological activity comparable to that of the free chlorin. In order to rationalize the physicochemical parameters of the carriers that control the biological activity, the new liposome formulations have been characterized by measuring (a) the zeta potential, (b) their capability of chlorin entrapping efficiency, i.e. entrapment efficacy, (c) the effect of storage on chlorin entrapment and (d) the localization of chlorin in the bilayer. The correlation of the physicochemical and biological features of formulations has allowed us to rationalize, to some extent, some of the parameters that may control the interactions with the biological environment. © 2008 American Chemical Society.

Bombelli, C., Bordi, F., Ferro, S., Giansanti, L., Jori, G., Mancini, G., et al. (2008). New cationic liposomes as vehicles of m-tetrahydroxyphenylchlorin in photodynamic therapy of infectious diseases. MOLECULAR PHARMACEUTICS, 5(4), 672-679 [10.1021/mp800037d].

New cationic liposomes as vehicles of m-tetrahydroxyphenylchlorin in photodynamic therapy of infectious diseases

MAZZUCA, CLAUDIA;MONTI, DONATO;VENANZI, MARIANO
2008-01-01

Abstract

Antimicrobial photodynamic therapy is emerging as a promising therapeutic modality for bacterial infections. For optimizing the antibacterial activity of the photosensitizer m-tetrahydroxy-phenylchlorin, it has been encapsulated in mixed cationic liposomes composed of different ratios of dimyristoyl-sn-glycero-phosphatidylcholine and any of four cationic surfactants derived from L-prolinol. The delivery efficiency of the different liposomes formulations has been evaluated on a methicillin-resistant Staphylococcus aureus bacterial strain (MRSA), and one of the tested formulations shows a biological activity comparable to that of the free chlorin. In order to rationalize the physicochemical parameters of the carriers that control the biological activity, the new liposome formulations have been characterized by measuring (a) the zeta potential, (b) their capability of chlorin entrapping efficiency, i.e. entrapment efficacy, (c) the effect of storage on chlorin entrapment and (d) the localization of chlorin in the bilayer. The correlation of the physicochemical and biological features of formulations has allowed us to rationalize, to some extent, some of the parameters that may control the interactions with the biological environment. © 2008 American Chemical Society.
2008
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore CHIM/03 - CHIMICA GENERALE E INORGANICA
Settore CHIM/01 - CHIMICA ANALITICA
Settore CHIM/02 - CHIMICA FISICA
English
Con Impact Factor ISI
3 tetrahydroxyphenylchlorin; cationic surfactant; dimyristoylphosphatidylcholine; drug carrier; liposome; meticillin; photosensitizing agent, antibacterial activity; bacterial cell; bacterial infection; conference paper; controlled study; correlation analysis; drug delivery system; drug formulation; encapsulation; methicillin resistant Staphylococcus aureus; molecular interaction; nonhuman; pharmacological parameters; photodynamic therapy; physical chemistry; priority journal; zeta potential, Cations; Chemistry, Physical; Liposomes; Mesoporphyrins; Molecular Structure; Photochemotherapy; Photosensitizing Agents; Staphylococcal Infections; Staphylococcus aureus
Bombelli, C., Bordi, F., Ferro, S., Giansanti, L., Jori, G., Mancini, G., et al. (2008). New cationic liposomes as vehicles of m-tetrahydroxyphenylchlorin in photodynamic therapy of infectious diseases. MOLECULAR PHARMACEUTICS, 5(4), 672-679 [10.1021/mp800037d].
Bombelli, C; Bordi, F; Ferro, S; Giansanti, L; Jori, G; Mancini, G; Mazzuca, C; Monti, D; Ricchelli, F; Sennato, S; Venanzi, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/11643
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 97
  • ???jsp.display-item.citation.isi??? 89
social impact